Key Insights
The European nuclear imaging solutions market, valued at €2.22 billion in 2025, is projected to experience steady growth, driven by a rising prevalence of chronic diseases like cancer and cardiovascular ailments necessitating advanced diagnostic techniques. Technological advancements in PET and SPECT imaging systems, offering improved image resolution and faster scan times, are further fueling market expansion. Increased adoption of minimally invasive procedures and a growing preference for early diagnosis contribute to the demand for nuclear imaging solutions across various applications, including oncology, cardiology, and neurology. The market is segmented by product type (equipment and radioisotopes) and application (SPECT and PET). Within radioisotopes, Technetium-99m (Tc-99m) currently holds a significant market share due to its widespread use in SPECT imaging. However, the market is witnessing a growing adoption of PET radioisotopes like Fluorine-18 (F-18), owing to their superior diagnostic capabilities in oncology. Germany, France, and the United Kingdom represent the largest national markets within Europe, driven by robust healthcare infrastructure and high healthcare expenditure.
Despite the positive growth trajectory, the market faces certain challenges. Regulatory hurdles associated with the handling and disposal of radioactive materials pose a significant constraint. Furthermore, the high cost of equipment and radioisotopes can limit accessibility, particularly in resource-constrained healthcare settings. Competition among major players like Siemens Healthineers, GE Healthcare, and Bracco Imaging is intense, leading to pricing pressures and a focus on innovation to maintain market share. Despite these challenges, the continued advancements in technology, coupled with the increasing demand for accurate and timely diagnostics, are expected to propel the growth of the European nuclear imaging solutions market throughout the forecast period (2025-2033), with a projected CAGR of 3.34%. The market is poised for significant expansion, particularly in the adoption of advanced PET imaging techniques and the development of novel radiopharmaceuticals.
Europe Nuclear Imaging Solutions Industry: 2019-2033 Market Report
This comprehensive report provides an in-depth analysis of the European nuclear imaging solutions industry, covering market size, growth drivers, competitive landscape, and future outlook from 2019 to 2033. The study period (2019-2024) and forecast period (2025-2033), with a base year of 2025 and estimated year of 2025, offer valuable insights for industry professionals, investors, and strategic decision-makers. The report segments the market by product (equipment, radioisotopes) and application (SPECT, PET), providing granular data for informed strategic planning. Key players such as Nordion Inc, Siemens Healthineers, and GE Healthcare are analyzed, revealing their market share and strategic moves. The report also delves into recent industry developments, regulatory landscape, and technological advancements impacting the sector.
Europe Nuclear Imaging Solutions Industry Market Structure & Innovation Trends
The European nuclear imaging solutions market exhibits a moderately concentrated structure with key players holding significant market shares. The market is driven by technological advancements in imaging equipment, radioisotopes, and data analytics. Stringent regulatory frameworks, including those from the European Medicines Agency (EMA), govern the development and approval of new products. The industry witnesses ongoing M&A activity, reflecting consolidation and expansion efforts. Substitute technologies, such as MRI and CT scans, exert competitive pressure. The end-user demographics are primarily hospitals, diagnostic centers, and research institutions.
- Market Concentration: Top 5 players hold an estimated xx% market share in 2025.
- Innovation Drivers: AI-powered image analysis, development of novel radiotracers, improved equipment sensitivity.
- Regulatory Landscape: EMA approvals are crucial for new product launches, influencing market entry timelines.
- M&A Activity: Recent years have seen xx Million in M&A deal value, with a focus on expanding product portfolios and geographical reach.
- Product Substitutes: Competition from alternative imaging modalities impacts market growth.
Europe Nuclear Imaging Solutions Industry Market Dynamics & Trends
The European nuclear imaging solutions market is experiencing significant growth, driven by the increasing prevalence of chronic diseases, rising demand for accurate and early disease diagnosis, and technological advancements enhancing image quality and diagnostic capabilities. The CAGR for the forecast period (2025-2033) is estimated at xx%. Market penetration of advanced imaging techniques like PET/CT is growing steadily. Consumer preferences are shifting towards minimally invasive procedures, driving demand for nuclear imaging. The competitive dynamics are characterized by intense rivalry among established players and emerging innovative companies, leading to continuous product improvements and price competition. Technological disruptions, such as AI-driven image analysis and the development of new radiotracers, are transforming the market landscape.
Dominant Regions & Segments in Europe Nuclear Imaging Solutions Industry
Western Europe, particularly Germany, France, and the UK, dominate the European nuclear imaging solutions market due to established healthcare infrastructure, high healthcare expenditure, and advanced medical technology adoption. The market is significantly segmented by product (equipment and radioisotopes) and application (SPECT and PET).
Key Drivers for Western Europe Dominance:
- Advanced healthcare infrastructure
- High healthcare expenditure per capita
- Strong presence of key market players
- Favorable regulatory environment
Dominant Segments:
- By Product: Equipment segment holds the largest market share, driven by technological advancements in PET/CT and SPECT systems. The radioisotope segment is experiencing growth due to the increasing demand for advanced diagnostic procedures.
- By Application: PET applications, particularly in oncology, are experiencing rapid growth, driven by the increasing incidence of cancer. SPECT applications maintain significant market share due to their established use in cardiology and neurology. The market size for Technetium-99m (Tc-99m) is estimated at xx Million in 2025.
Europe Nuclear Imaging Solutions Industry Product Innovations
Recent product innovations focus on improving image resolution, reducing radiation exposure, and enhancing diagnostic accuracy. Advanced PET/CT scanners with improved detectors and reconstruction algorithms provide superior image quality. The development of novel radiotracers with enhanced specificity and sensitivity is revolutionizing the field. AI-powered image analysis tools are streamlining workflows and improving diagnostic efficiency, improving market fit and gaining competitive advantages.
Report Scope & Segmentation Analysis
This report comprehensively segments the European nuclear imaging solutions market by product (Equipment, Radioisotope) and further by radioisotope type (SPECT: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium (Ga-67), Other SPECT Radioisotopes; PET: Fluorine-18 (F-18), Rubidium-82 (Rb-82), Other PET Radioisotopes) and application (SPECT Applications, Other SPECT Applications, PET Applications). Each segment's market size, growth projections, and competitive dynamics are analyzed in detail. The projected growth in the Equipment segment is driven by technological advancements and increased demand, while the Radioisotope segment growth is driven by the increasing use of PET and SPECT imaging.
Key Drivers of Europe Nuclear Imaging Solutions Industry Growth
The European nuclear imaging solutions market is driven by several key factors: rising prevalence of chronic diseases such as cancer and cardiovascular diseases leading to increased diagnostic needs; advancements in imaging technology providing higher resolution and sensitivity; government initiatives and funding for healthcare infrastructure improvements; growing adoption of PET/CT scans for precise diagnosis and treatment planning; and increased investment in research and development of new radiopharmaceuticals and imaging agents.
Challenges in the Europe Nuclear Imaging Solutions Industry Sector
The industry faces challenges including the high cost of equipment and radioisotopes limiting accessibility; regulatory hurdles and lengthy approval processes for new products; potential risks associated with radiation exposure necessitating stringent safety protocols; and supply chain disruptions impacting the availability of crucial components and radioisotopes. These factors collectively constrain market growth and necessitate effective mitigation strategies.
Emerging Opportunities in Europe Nuclear Imaging Solutions Industry
Emerging opportunities include the growing adoption of theranostics (combination of diagnostics and therapeutics), personalized medicine leveraging molecular imaging data, expansion into underserved markets, development of new radiotracers for specific diseases, and integration of AI and machine learning for image analysis and diagnosis. These advancements offer significant growth potential and will reshape the industry.
Leading Players in the Europe Nuclear Imaging Solutions Industry Market
- Nordion Inc
- Siemens Healthineers (Siemens Healthineers)
- GE Healthcare (GE Healthcare)
- Bracco Imaging SpA
- Cardinal Health Inc
- Novartis AG (Advanced Accelerator Applications)
- NTP Radioisotopes SOC
- Koninklijke Philips NV (Koninklijke Philips NV)
- Canon Medical Systems Corporation (Canon Medical Systems Corporation)
- Curium
- Merck KGaA (Sigma-Aldrich)
- *List Not Exhaustive
Key Developments in Europe Nuclear Imaging Solutions Industry Industry
September 2023: Lantheus Holdings, Inc. reported that PYLARIFY AI data will be presented at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting in Vienna, Austria. This highlights the growing importance of AI in nuclear medicine.
December 2022: The European Commission (EC) approved Novartis's Pluvicto for the treatment of prostate cancer. This approval marks a significant advancement in targeted radioligand therapy and expands treatment options for patients.
Future Outlook for Europe Nuclear Imaging Solutions Industry Market
The European nuclear imaging solutions market is poised for continued growth, driven by technological advancements, increasing prevalence of chronic diseases, and rising healthcare expenditure. Strategic opportunities lie in developing innovative products, expanding into emerging markets, and leveraging AI and data analytics to enhance diagnostic capabilities. The market's future is bright, with substantial potential for growth and innovation in the coming years.
Europe Nuclear Imaging Solutions Industry Segmentation
-
1. Product
- 1.1. Equipment
-
1.2. Radioisotope
-
1.2.1. SPECT Radioisotopes
- 1.2.1.1. Technetium-99m (TC-99m)
- 1.2.1.2. Thallium-201 (TI-201)
- 1.2.1.3. Gallium(Ga-67)
- 1.2.1.4. Other SPECT Radioisotopes
-
1.2.2. PET Radioisotopes
- 1.2.2.1. Fluorine-18 (F-18)
- 1.2.2.2. Rubidium-82 (RB-82)
- 1.2.2.3. Other PET Radioisotopes
-
1.2.1. SPECT Radioisotopes
-
2. Application
-
2.1. SPECT Applications
- 2.1.1. Cardiology
- 2.1.2. Neurology
- 2.1.3. Thyroid
- 2.1.4. Other SPECT Applications
-
2.2. PET Applications
- 2.2.1. Oncology
- 2.2.2. Other PET Applications
-
2.1. SPECT Applications
Europe Nuclear Imaging Solutions Industry Segmentation By Geography
- 1. Germany
- 2. United Kingdom
- 3. France
- 4. Italy
- 5. Spain
- 6. Rest of Europe
Europe Nuclear Imaging Solutions Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 3.34% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise in Prevalence of Cancer and Cardiac Disorders; Growth in Applications of Nuclear Medicine and Imaging and Rising Technological Advancements
- 3.3. Market Restrains
- 3.3.1. Regulatory Issues and Lack of Reimbursement
- 3.4. Market Trends
- 3.4.1. Equipment Segment Expects to Witness Significant Growth Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Equipment
- 5.1.2. Radioisotope
- 5.1.2.1. SPECT Radioisotopes
- 5.1.2.1.1. Technetium-99m (TC-99m)
- 5.1.2.1.2. Thallium-201 (TI-201)
- 5.1.2.1.3. Gallium(Ga-67)
- 5.1.2.1.4. Other SPECT Radioisotopes
- 5.1.2.2. PET Radioisotopes
- 5.1.2.2.1. Fluorine-18 (F-18)
- 5.1.2.2.2. Rubidium-82 (RB-82)
- 5.1.2.2.3. Other PET Radioisotopes
- 5.1.2.1. SPECT Radioisotopes
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. SPECT Applications
- 5.2.1.1. Cardiology
- 5.2.1.2. Neurology
- 5.2.1.3. Thyroid
- 5.2.1.4. Other SPECT Applications
- 5.2.2. PET Applications
- 5.2.2.1. Oncology
- 5.2.2.2. Other PET Applications
- 5.2.1. SPECT Applications
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. Germany
- 5.3.2. United Kingdom
- 5.3.3. France
- 5.3.4. Italy
- 5.3.5. Spain
- 5.3.6. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. Germany Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Equipment
- 6.1.2. Radioisotope
- 6.1.2.1. SPECT Radioisotopes
- 6.1.2.1.1. Technetium-99m (TC-99m)
- 6.1.2.1.2. Thallium-201 (TI-201)
- 6.1.2.1.3. Gallium(Ga-67)
- 6.1.2.1.4. Other SPECT Radioisotopes
- 6.1.2.2. PET Radioisotopes
- 6.1.2.2.1. Fluorine-18 (F-18)
- 6.1.2.2.2. Rubidium-82 (RB-82)
- 6.1.2.2.3. Other PET Radioisotopes
- 6.1.2.1. SPECT Radioisotopes
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. SPECT Applications
- 6.2.1.1. Cardiology
- 6.2.1.2. Neurology
- 6.2.1.3. Thyroid
- 6.2.1.4. Other SPECT Applications
- 6.2.2. PET Applications
- 6.2.2.1. Oncology
- 6.2.2.2. Other PET Applications
- 6.2.1. SPECT Applications
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. United Kingdom Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Equipment
- 7.1.2. Radioisotope
- 7.1.2.1. SPECT Radioisotopes
- 7.1.2.1.1. Technetium-99m (TC-99m)
- 7.1.2.1.2. Thallium-201 (TI-201)
- 7.1.2.1.3. Gallium(Ga-67)
- 7.1.2.1.4. Other SPECT Radioisotopes
- 7.1.2.2. PET Radioisotopes
- 7.1.2.2.1. Fluorine-18 (F-18)
- 7.1.2.2.2. Rubidium-82 (RB-82)
- 7.1.2.2.3. Other PET Radioisotopes
- 7.1.2.1. SPECT Radioisotopes
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. SPECT Applications
- 7.2.1.1. Cardiology
- 7.2.1.2. Neurology
- 7.2.1.3. Thyroid
- 7.2.1.4. Other SPECT Applications
- 7.2.2. PET Applications
- 7.2.2.1. Oncology
- 7.2.2.2. Other PET Applications
- 7.2.1. SPECT Applications
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. France Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Equipment
- 8.1.2. Radioisotope
- 8.1.2.1. SPECT Radioisotopes
- 8.1.2.1.1. Technetium-99m (TC-99m)
- 8.1.2.1.2. Thallium-201 (TI-201)
- 8.1.2.1.3. Gallium(Ga-67)
- 8.1.2.1.4. Other SPECT Radioisotopes
- 8.1.2.2. PET Radioisotopes
- 8.1.2.2.1. Fluorine-18 (F-18)
- 8.1.2.2.2. Rubidium-82 (RB-82)
- 8.1.2.2.3. Other PET Radioisotopes
- 8.1.2.1. SPECT Radioisotopes
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. SPECT Applications
- 8.2.1.1. Cardiology
- 8.2.1.2. Neurology
- 8.2.1.3. Thyroid
- 8.2.1.4. Other SPECT Applications
- 8.2.2. PET Applications
- 8.2.2.1. Oncology
- 8.2.2.2. Other PET Applications
- 8.2.1. SPECT Applications
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Italy Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Equipment
- 9.1.2. Radioisotope
- 9.1.2.1. SPECT Radioisotopes
- 9.1.2.1.1. Technetium-99m (TC-99m)
- 9.1.2.1.2. Thallium-201 (TI-201)
- 9.1.2.1.3. Gallium(Ga-67)
- 9.1.2.1.4. Other SPECT Radioisotopes
- 9.1.2.2. PET Radioisotopes
- 9.1.2.2.1. Fluorine-18 (F-18)
- 9.1.2.2.2. Rubidium-82 (RB-82)
- 9.1.2.2.3. Other PET Radioisotopes
- 9.1.2.1. SPECT Radioisotopes
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. SPECT Applications
- 9.2.1.1. Cardiology
- 9.2.1.2. Neurology
- 9.2.1.3. Thyroid
- 9.2.1.4. Other SPECT Applications
- 9.2.2. PET Applications
- 9.2.2.1. Oncology
- 9.2.2.2. Other PET Applications
- 9.2.1. SPECT Applications
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. Spain Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Equipment
- 10.1.2. Radioisotope
- 10.1.2.1. SPECT Radioisotopes
- 10.1.2.1.1. Technetium-99m (TC-99m)
- 10.1.2.1.2. Thallium-201 (TI-201)
- 10.1.2.1.3. Gallium(Ga-67)
- 10.1.2.1.4. Other SPECT Radioisotopes
- 10.1.2.2. PET Radioisotopes
- 10.1.2.2.1. Fluorine-18 (F-18)
- 10.1.2.2.2. Rubidium-82 (RB-82)
- 10.1.2.2.3. Other PET Radioisotopes
- 10.1.2.1. SPECT Radioisotopes
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. SPECT Applications
- 10.2.1.1. Cardiology
- 10.2.1.2. Neurology
- 10.2.1.3. Thyroid
- 10.2.1.4. Other SPECT Applications
- 10.2.2. PET Applications
- 10.2.2.1. Oncology
- 10.2.2.2. Other PET Applications
- 10.2.1. SPECT Applications
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. Rest of Europe Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - by Product
- 11.1.1. Equipment
- 11.1.2. Radioisotope
- 11.1.2.1. SPECT Radioisotopes
- 11.1.2.1.1. Technetium-99m (TC-99m)
- 11.1.2.1.2. Thallium-201 (TI-201)
- 11.1.2.1.3. Gallium(Ga-67)
- 11.1.2.1.4. Other SPECT Radioisotopes
- 11.1.2.2. PET Radioisotopes
- 11.1.2.2.1. Fluorine-18 (F-18)
- 11.1.2.2.2. Rubidium-82 (RB-82)
- 11.1.2.2.3. Other PET Radioisotopes
- 11.1.2.1. SPECT Radioisotopes
- 11.2. Market Analysis, Insights and Forecast - by Application
- 11.2.1. SPECT Applications
- 11.2.1.1. Cardiology
- 11.2.1.2. Neurology
- 11.2.1.3. Thyroid
- 11.2.1.4. Other SPECT Applications
- 11.2.2. PET Applications
- 11.2.2.1. Oncology
- 11.2.2.2. Other PET Applications
- 11.2.1. SPECT Applications
- 11.1. Market Analysis, Insights and Forecast - by Product
- 12. Germany Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 13. France Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 14. Italy Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 15. United Kingdom Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 16. Netherlands Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 17. Sweden Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 18. Rest of Europe Europe Nuclear Imaging Solutions Industry Analysis, Insights and Forecast, 2019-2031
- 19. Competitive Analysis
- 19.1. Market Share Analysis 2024
- 19.2. Company Profiles
- 19.2.1 Nordion Inc
- 19.2.1.1. Overview
- 19.2.1.2. Products
- 19.2.1.3. SWOT Analysis
- 19.2.1.4. Recent Developments
- 19.2.1.5. Financials (Based on Availability)
- 19.2.2 Siemens Healthineers
- 19.2.2.1. Overview
- 19.2.2.2. Products
- 19.2.2.3. SWOT Analysis
- 19.2.2.4. Recent Developments
- 19.2.2.5. Financials (Based on Availability)
- 19.2.3 GE Healthcare
- 19.2.3.1. Overview
- 19.2.3.2. Products
- 19.2.3.3. SWOT Analysis
- 19.2.3.4. Recent Developments
- 19.2.3.5. Financials (Based on Availability)
- 19.2.4 Bracco Imaging SpA
- 19.2.4.1. Overview
- 19.2.4.2. Products
- 19.2.4.3. SWOT Analysis
- 19.2.4.4. Recent Developments
- 19.2.4.5. Financials (Based on Availability)
- 19.2.5 Cardinal Health Inc
- 19.2.5.1. Overview
- 19.2.5.2. Products
- 19.2.5.3. SWOT Analysis
- 19.2.5.4. Recent Developments
- 19.2.5.5. Financials (Based on Availability)
- 19.2.6 Novartis AG (Advanced Accelerator Applications)
- 19.2.6.1. Overview
- 19.2.6.2. Products
- 19.2.6.3. SWOT Analysis
- 19.2.6.4. Recent Developments
- 19.2.6.5. Financials (Based on Availability)
- 19.2.7 NTP Radioisotopes SOC
- 19.2.7.1. Overview
- 19.2.7.2. Products
- 19.2.7.3. SWOT Analysis
- 19.2.7.4. Recent Developments
- 19.2.7.5. Financials (Based on Availability)
- 19.2.8 Koninklijke Philips NV
- 19.2.8.1. Overview
- 19.2.8.2. Products
- 19.2.8.3. SWOT Analysis
- 19.2.8.4. Recent Developments
- 19.2.8.5. Financials (Based on Availability)
- 19.2.9 Canon Medical Systems Corporation
- 19.2.9.1. Overview
- 19.2.9.2. Products
- 19.2.9.3. SWOT Analysis
- 19.2.9.4. Recent Developments
- 19.2.9.5. Financials (Based on Availability)
- 19.2.10 Curium
- 19.2.10.1. Overview
- 19.2.10.2. Products
- 19.2.10.3. SWOT Analysis
- 19.2.10.4. Recent Developments
- 19.2.10.5. Financials (Based on Availability)
- 19.2.11 Merck KGaA (Sigma-Aldrich)*List Not Exhaustive
- 19.2.11.1. Overview
- 19.2.11.2. Products
- 19.2.11.3. SWOT Analysis
- 19.2.11.4. Recent Developments
- 19.2.11.5. Financials (Based on Availability)
- 19.2.1 Nordion Inc
List of Figures
- Figure 1: Europe Nuclear Imaging Solutions Industry Revenue Breakdown (Million, %) by Product 2024 & 2032
- Figure 2: Europe Nuclear Imaging Solutions Industry Share (%) by Company 2024
List of Tables
- Table 1: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 3: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 4: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 5: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 6: Germany Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 7: France Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 8: Italy Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: United Kingdom Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 10: Netherlands Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 11: Sweden Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: Rest of Europe Europe Nuclear Imaging Solutions Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 14: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 15: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 16: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 17: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 18: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 19: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 20: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 21: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 22: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 23: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 24: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 25: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 26: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 27: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 28: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Product 2019 & 2032
- Table 29: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Application 2019 & 2032
- Table 30: Europe Nuclear Imaging Solutions Industry Revenue Million Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Europe Nuclear Imaging Solutions Industry?
The projected CAGR is approximately 3.34%.
2. Which companies are prominent players in the Europe Nuclear Imaging Solutions Industry?
Key companies in the market include Nordion Inc, Siemens Healthineers, GE Healthcare, Bracco Imaging SpA, Cardinal Health Inc, Novartis AG (Advanced Accelerator Applications), NTP Radioisotopes SOC, Koninklijke Philips NV, Canon Medical Systems Corporation, Curium, Merck KGaA (Sigma-Aldrich)*List Not Exhaustive.
3. What are the main segments of the Europe Nuclear Imaging Solutions Industry?
The market segments include Product, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 2.22 Million as of 2022.
5. What are some drivers contributing to market growth?
Rise in Prevalence of Cancer and Cardiac Disorders; Growth in Applications of Nuclear Medicine and Imaging and Rising Technological Advancements.
6. What are the notable trends driving market growth?
Equipment Segment Expects to Witness Significant Growth Over the Forecast Period.
7. Are there any restraints impacting market growth?
Regulatory Issues and Lack of Reimbursement.
8. Can you provide examples of recent developments in the market?
September 2023: Lantheus Holdings, Inc. reported PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held in Vienna, Austria.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Europe Nuclear Imaging Solutions Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Europe Nuclear Imaging Solutions Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Europe Nuclear Imaging Solutions Industry?
To stay informed about further developments, trends, and reports in the Europe Nuclear Imaging Solutions Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
